These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 12935946)

  • 1. The pain of antisense: in vivo application of antisense oligonucleotides for functional genomics in pain and analgesia.
    Stone LS; Vulchanova L
    Adv Drug Deliv Rev; 2003 Aug; 55(8):1081-112. PubMed ID: 12935946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uptake of antisense oligonucleotides and functional block of acetylcholine receptor subunit gene expression in primary embryonic neurons.
    Yu C; Brussaard AB; Yang X; Listerud M; Role LW
    Dev Genet; 1993; 14(4):296-304. PubMed ID: 7693387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotide technology: from EST to therapeutics.
    Giles RV
    Curr Opin Mol Ther; 2000 Jun; 2(3):238-52. PubMed ID: 11249617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents.
    Brysch W; Schlingensiepen KH
    Cell Mol Neurobiol; 1994 Oct; 14(5):557-68. PubMed ID: 7621513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten years of antisense inhibition of brain G-protein-coupled receptor function.
    Van Oekelen D; Luyten WH; Leysen JE
    Brain Res Brain Res Rev; 2003 May; 42(2):123-42. PubMed ID: 12738054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in antisense oligonucleotide therapeutics.
    Crooke ST; Bennett CF
    Annu Rev Pharmacol Toxicol; 1996; 36():107-29. PubMed ID: 8725384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense oligonucleotides for therapeutic intervention.
    Eck SL; Nabel GJ
    Curr Opin Biotechnol; 1991 Dec; 2(6):897-904. PubMed ID: 1367966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo.
    Wang L; Prakash RK; Stein CA; Koehn RK; Ruffner DE
    Antisense Nucleic Acid Drug Dev; 2003; 13(3):169-89. PubMed ID: 12954117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide-oligonucleotide hybrids in antisense therapy.
    Pierce TL; White AR; Tregear GW; Sexton PM
    Mini Rev Med Chem; 2005 Jan; 5(1):41-55. PubMed ID: 15638791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
    Oberbauer R
    Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense oligonucleotide therapy in the management of bladder cancer.
    So A; Rocchi P; Gleave M
    Curr Opin Urol; 2005 Sep; 15(5):320-7. PubMed ID: 16093856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of antisense technology to therapeutics.
    Heidenreich O; Kang SH; Xu X; Nerenberg M
    Mol Med Today; 1995 Jun; 1(3):128-33. PubMed ID: 9415148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of antisense oligonucleotide inhibitors of protein expression.
    Cooper SR; Taylor JK; Miraglia LJ; Dean NM
    Pharmacol Ther; 1999; 82(2-3):427-35. PubMed ID: 10454217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of antisense oligonucleotides: advantages, controls, and cardiovascular tissue.
    Golden T; Dean NM; Honkanen RE
    Microcirculation; 2002 Jan; 9(1):51-64. PubMed ID: 11896559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides.
    Goyenvalle A; Jimenez-Mallebrera C; van Roon W; Sewing S; Krieg AM; Arechavala-Gomeza V; Andersson P
    Nucleic Acid Ther; 2023 Jan; 33(1):1-16. PubMed ID: 36579950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential therapeutic application of antisense oligonucleotides in the treatment of ocular diseases.
    Danis RP; Henry SP; Ciulla TA
    Expert Opin Pharmacother; 2001 Feb; 2(2):277-91. PubMed ID: 11336586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of clomipramine and amitriptyline analgesia by an antisense oligonucleotide to mKv1.1, a mouse Shaker-like K+ channel.
    Galeotti N; Ghelardini C; Capaccioli S; Quattrone A; Nicolin A; Bartolini A
    Eur J Pharmacol; 1997 Jul; 330(1):15-25. PubMed ID: 9228410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense and/or immunostimulatory oligonucleotide therapeutics.
    Agrawal S; Kandimalla ER
    Curr Cancer Drug Targets; 2001 Nov; 1(3):197-209. PubMed ID: 12188879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capillary gel electrophoresis and antisense therapeutics. Analysis of DNA analogs.
    DeDionisio LA; Lloyd DH
    J Chromatogr A; 1996 May; 735(1-2):191-208. PubMed ID: 8767742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.